MARKET

LGND

LGND

Ligand Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

81.56
-1.95
-2.34%
Closed 16:00 05/24 EDT
OPEN
82.15
PREV CLOSE
83.51
HIGH
82.67
LOW
79.30
VOLUME
132.81K
TURNOVER
--
52 WEEK HIGH
169.98
52 WEEK LOW
77.80
MARKET CAP
1.38B
P/E (TTM)
60.34
1D
5D
1M
3M
1Y
5Y
Zacks.com featured highlights include Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals
Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals are part of zacks screen of the week article.
Zacks · 6d ago
Are Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Mixed Financials Driving The Negative Sentiment?
Ligand Pharmaceuticals (NASDAQ:LGND) has had a rough three months with its share price down 26%. It seems that the...
Simply Wall St. · 6d ago
Detoxify Your Holdings by Steering Clear of These 4 Stocks
Getting rid of fundamentally weak toxic stocks is important to shield your portfolio from losses. MSGE, MTLS, INNV and LGND are a few toxic stocks according to our model that you should dump now.
Zacks · 05/17 12:42
10 Biggest Price Target Changes For Monday
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading.
Benzinga · 05/16 11:53
Stephens Adjusts Ligand Pharmaceuticals' Price Target to $130 from $153, Keeps Overweight Rating
MT Newswires · 05/16 09:59
Ligand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on Track
Ligand (LGND) reports encouraging first-quarter 2022 numbers by beating estimates on both counts. However, Captisol sales get hurt by lower demand for COVID-19 therapies.
Zacks · 05/05 15:22
Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates
Ligand (LGND) delivered earnings and revenue surprises of -4.92% and 33.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 00:55
Ligand Pharmaceuticals Non-GAAP EPS of $0.76 beats by $0.10, revenue of $45.69M beats by $11.48M
Ligand Pharmaceuticals press release (NASDAQ:LGND): Q1 Non-GAAP EPS of $0.76 beats by $0.10. Revenue of $45.69M (-17.2% Y/Y) beats by $11.48M. Outlook: Ligand is reaffirming 2022 revenue guidance for the
Seekingalpha · 05/04 20:52
More
No Data
Learn about the latest financial forecast of LGND. Analyze the recent business situations of Ligand Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
85.71%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LGND stock price target is 184.29 with a high estimate of 310.00 and a low estimate of 130.00.
High310.00
Average184.29
Low130.00
Current 81.56
EPS
Actual
Estimate
0.450.901.351.80
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 407
Institutional Holdings: 20.60M
% Owned: 122.20%
Shares Outstanding: 16.86M
TypeInstitutionsShares
Increased
69
326.49K
New
32
236.01K
Decreased
82
522.05K
Sold Out
14
121.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
John Kozarich
President/Chief Operating Officer
Matthew Foehr
Chief Executive Officer/Director
John Higgins
Chief Financial Officer/Executive Vice President - Finance
Matthew Korenberg
Senior Vice President/General Counsel/Secretary
Charles Berkman
Independent Director
Jason Aryeh
Independent Director
Sarah Boyce
Independent Director
Jennifer Cochran
Independent Director
Todd Davis
Independent Director
Nancy Gray
Independent Director
John Lamattina
Independent Director
Sunil Patel
Independent Director
Stephen Sabba
No Data
No Data
About LGND
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's technology includes Captisol Technology, OmniAb Technologies (OMT), Icagen Ion Channel Technology Platform, Pelican Expression Technology platform and Liver Targeting Prodrug (LTP) Technology to assist companies in their work toward securing prescription drug and biologic approvals. It has partnerships and license agreements with over 130 pharmaceutical and biotechnology companies and over 300 programs that are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its partners and licensees have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.

Webull offers kinds of Ligand Pharmaceuticals Inc. stock information, including NASDAQ:LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.